BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27663565)

  • 1. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.
    Dhir M; Shrestha R; Steel JL; Marsh JW; Tsung A; Tublin ME; Amesur NB; Orons PD; Santos E; Geller DA
    Ann Surg Oncol; 2017 Feb; 24(2):450-459. PubMed ID: 27663565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
    Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
    Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
    Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
    Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil Lymphocyte Ratio and Transarterial Chemoembolization in Neuroendocrine Tumor Metastases.
    McDermott SM; Saunders ND; Schneider EB; Strosberg D; Onesti J; Dillhoff M; Schmidt CR; Shirley LA
    J Surg Res; 2018 Dec; 232():369-375. PubMed ID: 30463743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.
    Luo Y; Ameli S; Pandey A; Khoshpouri P; Ghasabeh MA; Pandey P; Li Z; Hu D; Kamel IR
    Eur Radiol; 2019 Nov; 29(11):5804-5812. PubMed ID: 31073860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.
    Assouline J; Cannella R; Porrello G; de Mestier L; Dioguardi Burgio M; Raynaud L; Hentic O; Cros J; Tselikas L; Ruszniewski P; Vullierme MP; Vilgrain V; Duran R; Ronot M
    Radiol Imaging Cancer; 2023 Jan; 5(1):e220051. PubMed ID: 36607243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period.
    Gruber-Rouh T; Naguib NN; Eichler K; Ackermann H; Zangos S; Trojan J; Beeres M; Harth M; Schulz B; Nour-Eldin A NE; Vogl TJ
    Int J Cancer; 2014 Mar; 134(5):1225-31. PubMed ID: 23960002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review.
    Shirley LA; McNally M; Chokshi R; Jones N; Tassone P; Guy G; Khabiri H; Schmidt C; Shah M; Bloomston M
    World J Surg Oncol; 2015 May; 13():167. PubMed ID: 25927667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes.
    Pericleous M; Caplin ME; Tsochatzis E; Yu D; Morgan-Rowe L; Toumpanakis C
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):61-9. PubMed ID: 26663886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
    Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
    Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.
    Fairweather M; Swanson R; Wang J; Brais LK; Dutton T; Kulke MH; Clancy TE
    Ann Surg Oncol; 2017 Aug; 24(8):2319-2325. PubMed ID: 28303430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
    Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
    J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.
    Arrese D; McNally ME; Chokshi R; Feria-Arias E; Schmidt C; Klemanski D; Gregory G; Khabiri H; Shah M; Bloomston M
    Ann Surg Oncol; 2013 Apr; 20(4):1114-20. PubMed ID: 23456380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.
    Strosberg D; Schneider EB; Onesti J; Saunders N; Konda B; Shah M; Dillhoff M; Schmidt CR; Shirley LA
    Ann Surg Oncol; 2018 Nov; 25(12):3613-3620. PubMed ID: 30182331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study.
    Pelage JP; Fohlen A; Mitry E; Lagrange C; Beauchet A; Rougier P
    Cardiovasc Intervent Radiol; 2017 Mar; 40(3):394-400. PubMed ID: 28035432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk?
    Kitano M; Davidson GW; Shirley LA; Schmidt CR; Guy GE; Khabiri H; Dowell JD; Shah MH; Bloomston M
    Ann Surg Oncol; 2016 Nov; 23(12):4008-4015. PubMed ID: 27393568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis.
    Kress O; Wagner HJ; Wied M; Klose KJ; Arnold R; Alfke H
    Digestion; 2003; 68(2-3):94-101. PubMed ID: 14593235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy.
    Vogl TJ; Mack MG; Balzer JO; Engelmann K; Straub R; Eichler K; Woitaschek D; Zangos S
    Radiology; 2003 Nov; 229(2):457-64. PubMed ID: 14500854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.